BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Dasatinib (BMS-354825) is an FDA-approved small molecular compound that was developed primarily to treat chronic myeloid leukemia (CML) as a multi-targeted tyrosine kinase inhibitor against wild-type BCR-ABL and SRC family kinases [2].